JW Pharmaceutical (001060) Fundamentals 2026 — P/E 7.9x, Revenue Analysis | SniperIQ
JW Pharmaceutical (001060) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩540.4B, trading at ₩23400.00 on the KSC. This SniperIQ fundamentals page covers JW Pharmaceutical's valuation (P/E 7.9x, P/B 1.4x), profitability (net margin 9.1%), revenue (₩774.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JW Pharmaceutical's market cap?
JW Pharmaceutical (001060) has a market capitalization of approximately ₩540.4B, trading at ₩23400.00 on the KSC. Market cap moves with the live share price.
What is JW Pharmaceutical's P/E ratio?
JW Pharmaceutical's trailing twelve-month P/E ratio is 7.9x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JW Pharmaceutical?
JW Pharmaceutical runs a net profit margin of 9.1%, a gross margin of 47.3%, and an operating margin of 13.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JW Pharmaceutical generate?
JW Pharmaceutical reported revenue of ₩774.8B for fiscal year 2025, with net income of ₩61.7B and earnings per share (EPS) of 2534.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JW Pharmaceutical pay a dividend?
JW Pharmaceutical offers a trailing dividend yield of about 2.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is JW Pharmaceutical financially healthy?
JW Pharmaceutical carries a debt-to-equity ratio of 0.14x and a current ratio of 1.46x, with a market beta of 0.96. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JW Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JW Pharmaceutical (001060) the key facts are: market cap ₩540.4B, P/E 7.9x, revenue ₩774.8B, 52-week range 20700-39250. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track JW Pharmaceutical's full fundamentals live
Get JW Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.